Medical cannabis: An oxymoron? Physicians’ perceptions of medical cannabis

Zolotov, Yuval; Vulfsons, Simon; Zarhin, Dana; Sznitman, Sharon R.

doi:10.1016/j.drugpo.2018.03.025

Cited by 70 publications

(105 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, given findings from previous studies, 33 there may be differences in provider support for discontinuing prescriptions depending on medication and patient condition. We did not ask participants to characterize physician responses to the lack of their prescription refills, but the interaction between patients and providers in this circumstance warrants further research.…”

Section: Discussionmentioning

confidence: 93%

“…32 Research from Israel, where MC was made available in 1990, has found physicians cur-rently split in their attitudes toward MC: some perceive its potential to treat conditions while acknowledging the limits of conventional medicine, whereas others view cannabis as incompatible with biomedicine and with the potential for dependency. 33 Patients in Canada have reported different levels of communication regarding MC with physicians depending on their conditions, as patients with arthritis and HIV exhibit greater likelihood of discussing MC with their physician than do patients with depression or anxiety. 34 Gendered patterns of cannabis use in the United States includes similar prevalence of recreational cannabis use in adolescence among males and females that increases among males during young adulthood.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gender Differences in Medical Cannabis Use: Symptoms Treated, Physician Support for Use, and Prescription Medication Discontinuation

Bruce

Grove

Foster

et al. 2021

Journal of Women's Health

View full text Add to dashboard Cite

Background: Medical cannabis (MC) utilization continues to expand in the United States, as a growing body of evidence supports the use of cannabis and cannabinoids in the treatment of a range of chronic conditions. To date, gender-related differences in MC use are not widely reported, and little is known regarding physicians' support of patients' use of MC to address symptoms associated with chronic conditions. Materials and Methods: We conducted a cross-sectional online survey of MC users in Illinois (n = 361). We summarized participants' qualifying conditions, symptoms treated with MC, perceived physician support for MC use, use of MC and prescription medications, then analyzed differences by participant gender. Results: Bivariate analyses indicate that men report higher levels of support for MC use from both specialist and primary care physicians. Women were significantly more likely to increase use of cannabis after acquiring an MC card, and to discontinue prescription medications through MC use. Multivariable analyses indicate that being a woman, using MC to treat multiple symptoms, and reporting higher levels of support for MC use from a primary care provider significantly increased the likelihood of discontinuing prescription medication through MC use. Discussion: Women are more likely to report decreased use of prescription medications to treat symptoms, and report lower levels of support from physicians for MC use. Future research on gender differences in this population may benefit from more detailed data related to symptomology, utilization, dosing, and outcomes associated with MC, and interactions with the health care system to extend these findings.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Gender Differences in Medical Cannabis Use: Symptoms Treated, Physician Support for Use, and Prescription Medication Discontinuation

Bruce

Grove

Foster

et al. 2021

Journal of Women's Health

View full text Add to dashboard Cite

show abstract

“…physicians being more open to prescribing a medication that is potentially addictive, drawing on their own observations and patient testimonials rather than relying on the science (Zolotov et al, 2018). In the subaltern realm efforts to standardise potencies and experiment with different cannabis varieties occurs, drawing on the science rhetoric of Statist medicine (Klein & Potter, 2018).…”

Section: The Story Unfoldsmentioning

confidence: 99%

Can the subaltern heal? Medical marijuana in Aotearoa New Zealand

Dew

Armstrong

2020

Journal of Sociology

View full text Add to dashboard Cite

In this article the concepts of statist medicine and subaltern therapeutics are used to provide insight into the debates over the therapeutic use of marijuana in cases of serious or terminal illness. In 2015 medical marijuana gained public attention in Aotearoa New Zealand as cases of people facing life-threatening conditions who wished to use marijuana for therapeutic purposes were given voice in the popular media. In Aotearoa New Zealand marijuana use is illegal for recreational purposes, but theoretically patients with particular conditions could gain access to medicinal forms of marijuana if health professionals, the Ministry of Health and the relevant government minister approved. This approval process is embedded within statist medicine’s regulatory regimes, where access can be provided on condition that the medication meets standards of safety and efficacy. Patients faced with the difficulty of negotiating the processes of statist medicine to access medical marijuana often reverted to illegal means of accessing the plant. Access to illegal forms of marijuana for medical purposes could be through ‘green fairies’, people who provided the plant for therapeutic purposes in a way that was distant from the criminalised recreational use of the drug obtained through ‘dealers’. The process of the state, patients and marijuana providers negotiating the regulation of therapeutic uses of marijuana provides insights into the role of statist medicine and subaltern therapeutics. The case of medical marijuana alerts us to the possibilities of other subaltern therapeutic practices that operate beyond the gaze of the state.

show abstract

“…More than 30 countries worldwide have now legalized access to medical cannabis [8,9]. Other countries have limited access to specific cannabinoid-based products.…”

Section: Introductionmentioning

confidence: 99%

Medical cannabis in supportive cancer care: lessons from Canada

Arboleda

Prosk

Cyr

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

Medical cannabis, or cannabinoid-based products, continues to grow in popularity globally, driving the evolution of regulatory access frameworks; cancer patients and caregivers often rely on guidance from their physicians regarding cannabinoid-based treatments. But the majority of healthcare practitioners still feel unprepared and insufficiently informed to make reasonable, evidence-based recommendations about medical cannabis. More than 30 countries worldwide have now legalized access to medical cannabis; yet various nations still face arduous regulatory challenges to fulfill the needs of patients, healthcare practitioners, and other medical stakeholders. This has affected the deployment of comprehensive medical cannabis access programs adapted to cultural and social realities. With a 20-year history of legal medical cannabis access and nearly 400,000 registered patients under its federal access program, Canada serves as a model for countries which are developing their regulatory frameworks. The Canadian clinical experience in cannabinoid-based treatments is also a valuable source of lessons for healthcare professionals who wish to better understand the current evidence examining medical cannabis for oncology patients.

show abstract

Medical cannabis: An oxymoron? Physicians’ perceptions of medical cannabis

Cited by 70 publications

References 51 publications

Gender Differences in Medical Cannabis Use: Symptoms Treated, Physician Support for Use, and Prescription Medication Discontinuation

Gender Differences in Medical Cannabis Use: Symptoms Treated, Physician Support for Use, and Prescription Medication Discontinuation

Can the subaltern heal? Medical marijuana in Aotearoa New Zealand

Medical cannabis in supportive cancer care: lessons from Canada

Contact Info

Product

Resources

About